The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Tumor Heterogeneity: Mechanisms and Bases for a Reliable Application of Molecular Marker Design
Open accessAbstract
Tumor heterogeneity is a confusing finding in the assessment of neoplasms, potentially resulting in inaccurate diagnostic, prognostic and predictive tests. This tumor heterogeneity is not always a random and unpredictable phenomenon, whose knowledge helps designing better tests. The biologic reasons for this intratumoral heterogeneity would then be important to understand both the natural history of neoplasms and the selection of test samples for reliable analysis. The main factors contributing to intratumoral heterogeneity inducing gene abnormalities or modifying its expression include: the gradient ischemic level within neoplasms, the action of tumor microenvironment (bidirectional interaction between tumor cells and stroma), mechanisms of intercellular transference of genetic information (exosomes), and differential mechanisms of sequence-independent modifications of genetic material and proteins. The intratumoral heterogeneity is at the origin of tumor progression and it is also the byproduct of the selection process during progression. Any analysis of heterogeneity mechanisms must be integrated within the process of segregation of genetic changes in tumor cells during the clonal expansion and progression of neoplasms. The evaluation of these mechanisms must also consider the redundancy and pleiotropism of molecular pathways, for which appropriate surrogate markers would support the presence or not of heterogeneous genetics and the main mechanisms responsible. This knowledge would constitute a solid scientific background for future therapeutic planning.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 2×
“These activities involve, on the one hand, regulation of genes that drive tumor progression [227,228], and, on the other hand, the induction of genes that may cause the opposite effect.”
BackgroundNowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 1×
“Intensive studies in the field of cancer genetics, and recent sequencing of cancer genomes and allowed the identification of cancer-type-specific subsets of genes that “drive” cancer progression [288,291,292].”
BackgroundHypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · cited 3×
“Hypoxia greatly influences cellular phenotypes by altering the expression of specific genes, makes the tumors more aggressive, and is an important contributor to intra- and inter-tumor cell diversity as revealed by the pronounced but non-uniform expression of hypoxia-driven genes in solid tumors [225].”
BackgroundInfluentialLessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Non-coding RNAs in human disease
Esteller, M. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3074 · Cited by 4,825
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
The tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
Hypoxia signalling in cancer and approaches to enforce tumour regression
Pouysségur, J., Dayan, F., & Mazure, N. M. (2006) · Nature · doi:10.1038/nature04871 · Cited by 1,676 · cited 2×
“These activities involve, on the one hand, regulation of genes that drive tumor progression [227,228], and, on the other hand, the induction of genes that may cause the opposite effect.”
BackgroundVEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Induction of tumors in mice by genomic hypomethylation
Gaudet, F., Hodgson, J. G., Eden, A., Jackson-Grusby, L., Dausman, J., Gray, J. W., Leonhardt, H., & Jaenisch, R. (2003) · Science · doi:10.1126/science.1083558 · Cited by 1,499 · cited 1×
“Undermethylation of DNA can favor mitotic recombination, leading to deletions and translocations [275,276], and it can also promote chromosomal rearrangements.”
BackgroundMacrophage polarization in tumour progression
Sica, A., Larghi, P., Mancino, A., Rubino, L., Porta, C., Totaro, M. G., Rimoldi, M., Biswas, S. K., Allavena, P., & Mantovani, A. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.03.004 · Cited by 1,241 · cited 1×
“wild-type mice, TAMs are predominantly M2-like macrophages, which are the cells primarily responsible for suppressing T cell-mediated antitumor responses and promoting tumor progression, metastasis, and angiogenesis [124-126].”
BackgroundHypoxia-Inducible Factors, Stem Cells, and Cancer
Keith, B., & Simon, M. C. (2007) · Cell · doi:10.1016/j.cell.2007.04.019 · Cited by 1,179
Yang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L. M., Carbone, D. P., & Lin, P. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.031 · Cited by 1,140
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Yang, L., Huang, J., Ren, X., Gorska, A. E., Chytil, A., Aakre, M., Carbone, D. P., Matrisian, L. M., Richmond, A., Lin, P. C., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.004 · Cited by 918 · cited 1×
“species (ROS) such as peroxynitrites, which cause DNA mutations that contribute to genetic instability and the proliferation of malignant cells [116]; (II) the production of proangiogenic factors such as vascular endothelial growth factor (VEGF), which promote tumor neovascularization [117]; and (III) the production o…”
BackgroundSinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M., & Ostrand-Rosenberg, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.2.977 · Cited by 847
PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention
Zhang, J., Grindley, J. C., Yin, T., Jayasinghe, S., He, X. C., Ross, J. T., Haug, J. S., Rupp, D., Porter-Westpfahl, K. S., Wiedemann, L. M., et al. (2006) · Nature · doi:10.1038/nature04747 · Cited by 817
Frequent clones of p53-mutated keratinocytes in normal human skin
Jonason, A. S., Kunala, S., Price, G. J., Restifo, R. J., Spinelli, H. M., Persing, J. A., Leffell, D. J., Tarone, R. E., & Brash, D. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14025 · Cited by 685 · cited 1×
“As the large majority of carcinogens can both (I) exert growth-suppression in the target tissue, possibly as a consequence of the inflicted DNA-damage [93], and (II) induce rare altered/initiated cells with a resistant phenotype [94], a clear outcome of such combined effects includes the possibility of a”
BackgroundA Cell-Surface Receptor for Lipocalin 24p3 Selectively Mediates Apoptosis and Iron Uptake
Devireddy, L. R., Gazin, C., Zhu, X., & Green, M. R. (2005) · Cell · doi:10.1016/j.cell.2005.10.027 · Cited by 672
The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase
Hiratsuka, S., Watanabe, A., Sakurai, Y., Akashi-Takamura, S., Ishibashi, S., Miyake, K., Shibuya, M., Akira, S., Aburatani, H., & Maru, Y. (2008) · Nature Cell Biology · doi:10.1038/ncb1794 · Cited by 642
Inflammation as a Tumor Promoter in Cancer Induction
Philip, M., Rowley, D. A., & Schreiber, H. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.06.006 · Cited by 640
Liu, D., & Hornsby, P. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3452 · Cited by 499
Defective DNA Repair and Neurodegenerative Disease
Rass, U., Ahel, I., & West, S. C. (2007) · Cell · doi:10.1016/j.cell.2007.08.043 · Cited by 358 · cited 2×
“Defects in DNA repair pathways can be associated with accumulation of widespread DNA damage [112].”
BackgroundThe hypoxic tumour microenvironment and metastatic progression
Subarsky, P., & Hill, R. P. (2003) · Clinical & Experimental Metastasis · doi:10.1023/a:1022939318102 · Cited by 327 · cited 1×
“a critical and fundamental role in metastasis formation [226].”
BackgroundEpigenetic inactivation of the premature aging Werner syndrome gene in human cancer
Agrelo, R., Cheng, W.-H., Setien, F., Ropero, S., Espada, J., Fraga, M. F., Herranz, M., Paz, M. F., Sanchez-Cespedes, M., Artiga, M. J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600645103 · Cited by 264 · cited 2×
“Such interactions can be seen when hypermethylation inactivates the CpG island of the promoter of the DNA-repair genes hMLH1, BRCA1, MGMT (O6-methylguanine–DNA methyltransferase), and the gene associated with Werner’s syndrome (WRN) [280-282].”
Background
Cited by
Pre-metastatic niches: organ-specific homes for metastases
Peinado, H., Zhang, H., Matei, I. R., Costa-Silva, B., Hoshino, A., Rodrigues, G., Psaila, B., Kaplan, R. N., Bromberg, J. F., Kang, Y., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.6 · Cited by 1,889
An overview of benzo [b] thiophene-based medicinal chemistry
Keri, R. S., Chand, K., Budagumpi, S., Balappa Somappa, S., Patil, S. A., & Nagaraja, B. M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.038 · Cited by 356
Papaccio, F., Paino, F., Regad, T., Papaccio, G., Desiderio, V., & Tirino, V. (2017) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0138 · Cited by 292
The Roles of ROS in Cancer Heterogeneity and Therapy
de Sá Junior, P. L., Câmara, D. A. D., Porcacchia, A. S., Fonseca, P. M. M., Jorge, S. D., Araldi, R. P., & Ferreira, A. K. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/2467940 · Cited by 287
Cancer Extracellular Vesicles: Next-Generation Diagnostic and Drug Delivery Nanotools
Palazzolo, S., Memeo, L., Hadla, M., Duzagac, F., Steffan, A., Perin, T., Canzonieri, V., Tuccinardi, T., Caligiuri, I., & Rizzolio, F. (2020) · Cancers · doi:10.3390/cancers12113165 · Cited by 34
Metadata
- Authors
- Diaz-Cano, S. J.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2012-02-13
- Volume
- 13
- Issue
- 2
- Pages
- 1951-2011
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2081606773
- Cited by
- 169
- References
- 29
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.